Download PDF
Exp Clin Endocrinol Diabetes 2008; 116(10): 592-599
DOI: 10.1055/s-2008-1065350
Article

© Georg Thieme Verlag KG Stuttgart · New York

Relationship of Serum Resistin Level to Traits of Metabolic Syndrome and Serum Paraoxonase 1 Activity in a Population with a Broad Range of Body Mass Index

L. Bajnok 1 , 4 , I. Seres 4 , Z. Varga 4 , S. Jeges 2 , A. Peti 3 , Z. Karanyi 4 , A. Juhasz 4 , E. Csongradi 4 , E. Mezosi 1 , 4 , E. V. Nagy 4 , G. Paragh 4
  • 11st Department of Medicine, School of Medicine, University of Pécs, Pécs, Hungary
  • 2Institute of Bioanalysis, School of Medicine and Applied Health Sciences, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
  • 3Institute of Laboratory Medicine, Faculty of Medicine, University of Pécs, Pécs, Hungary
  • 41st Department of Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary
Further Information

Publication History

received 08.11.2007 first decision 16.01.2008

accepted 11.03.2008

Publication Date:
09 May 2008 (online)

Also available at
    Permissions and Reprints

Abstract

The relationship between resistin, one of the adipokines, and metabolic syndrome is not fully elucidated. Altered activity of the HDL-associated antioxidant enzyme paraoxonase 1 (PON1) that participates in the antioxidant defense mechanisms of HDL may have an important role in the obesity-related accelerated atherosclerosis. Inverse associations of PON1 with obesity and serum levels of leptin have been demonstrated. Our aim was to investigate the association of serum levels of resistin with (i) PON1 activity, and (ii) parameters of metabolic syndrome, including some that are additional for research. A total of 74 Caucasian subjects were recruited into the study and divided into 3 age and sex-matched groups. Group 1, 25 non-diabetic overweight/obese subjects with BMI of 28–39.9 kg/m2; group 2, 25 non-diabetic obese patients with BMI ≥40 kg/m2; and the control group 3, 24 healthy, normal-weight control subjects. Serum levels of resistin were correlated negatively with BMI (r=−0.27, P<0.05), waist circumference (r=−0.28, P<0.05), serum levels of leptin (r=−0.28, P<0.05), non-esterified fatty acids (NEFA) (r=−0.23, P<0.05), and HbA1C (r=−0.26, P<0.05), systolic BP (r=−0.28, P<0.05), and lipid peroxidation (measured by TBARS) (r=−0.40, P<0.01), and correlated positively with PON1 (r=0.24, P<0.05). No association was detected between the serum concentrations of resistin and the following investigated parameters: diastolic BP, levels of uric acid, glucose, insulin, or insulin resistance (measured by homeostasis model assessment, HOMA-IR), triglyceride, total cholesterol, LDL-C, and HDL-C. During multiple regression analyses BMI and TBARS were independent predictors of PON1, while age, gender, blood pressure, HOMA-IR, LDL-C, HDL-C, and resistin were not.

Conclusions: Among the study subjects, serum levels of resistin showed a positive, although not independent correlation with serum PON1, and a negative correlation with numerous parameters of the metabolic syndrome (i.e. adiposity, blood pressure, levels of leptin, free fatty acid, glycosylated hemoglobin, and lipid peroxidation). BMI and TBARS are independent predictors of PON1 activity.

Key words

obesity - resistin - serum paraoxonase 1 - metabolic syndrome

References

  • 1 Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.  Arterioscler Thromb Vasc Biol. 1995;  15 1812-1818
    CrossrefPubMedSearch in Google Scholar
  • 2 Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group . The metabolic syndrome–a new worldwide definition.  Lancet. 2005;  366 1059-1062
    CrossrefPubMedSearch in Google Scholar
  • 3 Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.  Free Radic Biol Med. 1999;  26 892-904
    CrossrefPubMedSearch in Google Scholar
  • 4 Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals.  Obes Res. 2003;  11 997-1001
    CrossrefPubMedSearch in Google Scholar
  • 5 Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters.  Metabolism. 2005;  54 471-475
    CrossrefPubMedSearch in Google Scholar
  • 6 Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans.  J Clin Endocrinol Metab. 2003;  88 5452-5455
    CrossrefPubMedSearch in Google Scholar
  • 7 Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture.  Biochem Biophys Res Commun. 2003;  300 674-678
    CrossrefPubMedSearch in Google Scholar
  • 8 Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls.  Horm Metab Res. 2002;  34 671-673
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females.  J Clin Endocrinol Metab. 2005;  90 1728-1733
    CrossrefPubMedSearch in Google Scholar
  • 10 Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes.  Clin Chim Acta. 2004;  339 57-63
    CrossrefPubMedSearch in Google Scholar
  • 11 Galli F, Varga Zs, Balla J, Ferraro B, Canestrari F, Floridi A, Kakuk G, Buoncristiani U. Vitamin E, lipid profile, and peroxidation in hemodialysis patients.  Kidney Int. 2001;  59 ((Suppl 78)) 148-154
    CrossrefPubMedSearch in Google Scholar
  • 12 Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues.  Curr Opin Lipidol. 2004;  15 261-267
    CrossrefPubMedSearch in Google Scholar
  • 13 Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy.  Arterioscler Thromb Vasc Biol. 2003;  23 111-116
    CrossrefPubMedSearch in Google Scholar
  • 14 Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.  Biochem Biophys Res Commun. 2003;  309 286-290
    CrossrefPubMedSearch in Google Scholar
  • 15 Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects.  J Clin Endocrinol Metab. 2003;  88 4848-4856
    CrossrefPubMedSearch in Google Scholar
  • 16 Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.  Exp Clin Endocrinol Diabetes. 2006;  114 544-548
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro.  FEBS Lett. 2002;  530 158-162
    CrossrefPubMedSearch in Google Scholar
  • 18 Mackness B, Durrington P, MacElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study.  Circulation. 2003;  107 2775-2779
    CrossrefPubMedSearch in Google Scholar
  • 19 Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus.  Atherosclerosis. 1991;  86 193-199
    CrossrefPubMedSearch in Google Scholar
  • 20 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Search in Google Scholar
  • 21 MacTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, MacTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.  J Clin Endocrinol Metab. 2003;  88 6098-6106
    CrossrefPubMedSearch in Google Scholar
  • 22 Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.  Biochem Biophys Res Commun. 2003;  300 472-476
    CrossrefPubMedSearch in Google Scholar
  • 23 Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance.  Clin Lab. 2003;  49 571-576
    PubMedSearch in Google Scholar
  • 24 Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.  J Clin Invest. 2003;  111 225-230
    CrossrefPubMedSearch in Google Scholar
  • 25 Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans.  Circulation. 2005;  111 932-939
    CrossrefPubMedSearch in Google Scholar
  • 26 Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.  J Biol Chem. 2006;  281 7657-7665
    CrossrefPubMedSearch in Google Scholar
  • 27 Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans.  Diabetes. 2001;  50 2199-2202
    CrossrefPubMedSearch in Google Scholar
  • 28 Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL, Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance.  Hum Reprod. 2004;  19 48-53
    CrossrefPubMedSearch in Google Scholar
  • 29 Seres I, Paragh G, Deschene E, Fulop Jr T, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging.  Exp Gerontol. 2004;  39 59-66
    CrossrefPubMedSearch in Google Scholar
  • 30 Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance.  Eur J Endocrinol. 2003;  149 331-335
    CrossrefPubMedSearch in Google Scholar
  • 31 Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase.  Drug Metab Dispos. 1991;  19 107-112
    PubMedSearch in Google Scholar
  • 32 Staiger H, Häring HU. Adipocytokines: Fat-derived humoral mediators of metabolic homeostasis.  Exp Clin Endocrinol Diabetes. 2005;  113 67-79
    Thieme ConnectPubMedSearch in Google Scholar
  • 33 Volarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians.  Diabetes. 2004;  53 1279-1284
    CrossrefPubMedSearch in Google Scholar
  • 34 Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein.  J Clin Invest. 1995;  96 2882-2891
    CrossrefPubMedSearch in Google Scholar
  • 35 Yang RZ, Huang Q, Xu A, MacLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW, Eison JA. Comparative studies of resistin expression and phylogenomics in human and mouse.  Biochem Biophys Res Commun. 2003;  310 927-935
    CrossrefPubMedSearch in Google Scholar
  • 36 Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.  J Clin Endocrinol Metab. 2003;  88 1730-1736
    CrossrefPubMedSearch in Google Scholar
  • 37 Yudkin JS. Inflammation, obesity, and the metabolic syndrome.  Horm Metab Res. 2007;  39 707-709
    Thieme ConnectPubMedSearch in Google Scholar

Correspondence

L. Bajnok

1st Department of Medicine

University of Pécs

School of Medicine

H-7624 Pécs

Ifjúság út 13

Hungary

Phone: 36/72/536 00/17 71

Fax: 36/72/536 14 8

Email: laszlo.bajnok@aok.pte.hu